308 related articles for article (PubMed ID: 10815931)
1. Lovastatin potentiates antitumor activity and attenuates cardiotoxicity of doxorubicin in three tumor models in mice.
Feleszko W; Mlynarczuk I; Balkowiec-Iskra EZ; Czajka A; Switaj T; Stoklosa T; Giermasz A; Jakóbisiak M
Clin Cancer Res; 2000 May; 6(5):2044-52. PubMed ID: 10815931
[TBL] [Abstract][Full Text] [Related]
2. Lovastatin potentiates antitumor activity of doxorubicin in murine melanoma via an apoptosis-dependent mechanism.
Feleszko W; Młynarczuk I; Olszewska D; Jalili A; Grzela T; Lasek W; Hoser G; Korczak-Kowalska G; Jakóbisiak M
Int J Cancer; 2002 Jul; 100(1):111-8. PubMed ID: 12115596
[TBL] [Abstract][Full Text] [Related]
3. Augmentation of antitumor activity of an antibody-interleukin 2 immunocytokine with chemotherapeutic agents.
Holden SA; Lan Y; Pardo AM; Wesolowski JS; Gillies SD
Clin Cancer Res; 2001 Sep; 7(9):2862-9. PubMed ID: 11555604
[TBL] [Abstract][Full Text] [Related]
4. Synergistic antitumor activity of tumor necrosis factor-alpha and lovastatin against MmB16 melanoma in mice.
Feleszko W; Lasek W; Gołab J; Jakóbisiak M
Neoplasma; 1995; 42(2):69-74. PubMed ID: 7617079
[TBL] [Abstract][Full Text] [Related]
5. Lovastatin enhances the antitumoral and apoptotic activity of doxorubicin in murine tumor models.
Rozados VR; Hinrichsen LI; Binda MM; Gervasoni SI; Matar P; Bonfil RD; Scharovsky OG
Oncol Rep; 2008 May; 19(5):1205-11. PubMed ID: 18425377
[TBL] [Abstract][Full Text] [Related]
6. Lovastatin and tumor necrosis factor-alpha exhibit potentiated antitumor effects against Ha-ras-transformed murine tumor via inhibition of tumor-induced angiogenesis.
Feleszko W; Bałkowiec EZ; Sieberth E; Marczak M; Dabrowska A; Giermasz A; Czajka A; Jakóbisiak M
Int J Cancer; 1999 May; 81(4):560-7. PubMed ID: 10225445
[TBL] [Abstract][Full Text] [Related]
7. Crucial role for interferon gamma in the synergism between tumor vasculature-targeted tumor necrosis factor alpha (NGR-TNF) and doxorubicin.
Sacchi A; Gasparri A; Curnis F; Bellone M; Corti A
Cancer Res; 2004 Oct; 64(19):7150-5. PubMed ID: 15466213
[TBL] [Abstract][Full Text] [Related]
8. Immunopharmacological and antitumor effects of second-generation immunomodulatory oligonucleotides containing synthetic CpR motifs.
Wang D; Li Y; Yu D; Song SS; Kandimalla ER; Agrawal S
Int J Oncol; 2004 Apr; 24(4):901-8. PubMed ID: 15010828
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of combinations of interferons and cytotoxic drugs in murine tumor models in vivo.
Harrison SD; Stevens JJ; Waud WR; Dykes DJ; Schmid SM; Griswold DP
J Biol Response Mod; 1990 Aug; 9(4):395-400. PubMed ID: 2118561
[TBL] [Abstract][Full Text] [Related]
10. Proapoptotic and antitumor activities of the HMG-CoA reductase inhibitor, lovastatin, against Dalton's lymphoma ascites tumor in mice.
Ajith TA; Harikumar KB; Thasna H; Sabu MC; Babitha NV
Clin Chim Acta; 2006 Apr; 366(1-2):322-8. PubMed ID: 16380106
[TBL] [Abstract][Full Text] [Related]
11. Antitumor activity of troxacitabine (Troxatyl) against anthracycline-resistant human xenografts.
Gourdeau H; Genne P; Kadhim S; Bibeau L; Duchamp O; Ouellet F; deMuys JM; Bouffard DY; Attardo G
Cancer Chemother Pharmacol; 2002 Dec; 50(6):490-6. PubMed ID: 12451476
[TBL] [Abstract][Full Text] [Related]
12. In vivo antitumor activity and host toxicity of methoxymorpholinyl doxorubicin: role of cytochrome P450 3A.
Quintieri L; Rosato A; Napoli E; Sola F; Geroni C; Floreani M; Zanovello P
Cancer Res; 2000 Jun; 60(12):3232-8. PubMed ID: 10866316
[TBL] [Abstract][Full Text] [Related]
13. Synergistic antitumor effects of a selective proteasome inhibitor and TNF in mice.
Golab J; Stoklosa T; Czajka A; Dabrowska A; Jakobisiak M; Zagozdzon R; Wojcik C; Marczak M; Wilk S
Anticancer Res; 2000; 20(3A):1717-21. PubMed ID: 10928098
[TBL] [Abstract][Full Text] [Related]
14. MX2, a morpholino anthracycline, as a new antitumor agent against drug-sensitive and multidrug-resistant human and murine tumor cells.
Watanabe M; Komeshima N; Nakajima S; Tsuruo T
Cancer Res; 1988 Dec; 48(23):6653-7. PubMed ID: 3180075
[TBL] [Abstract][Full Text] [Related]
15. Synergistic activity of recombinant human endostatin in combination with adriamycin: analysis of in vitro activity on endothelial cells and in vivo tumor progression in an orthotopic murine mammary carcinoma model.
Plum SM; Hanson AD; Volker KM; Vu HA; Sim BK; Fogler WE; Fortier AH
Clin Cancer Res; 2003 Oct; 9(12):4619-26. PubMed ID: 14555538
[TBL] [Abstract][Full Text] [Related]
16. Fluoxetine inhibits multidrug resistance extrusion pumps and enhances responses to chemotherapy in syngeneic and in human xenograft mouse tumor models.
Peer D; Dekel Y; Melikhov D; Margalit R
Cancer Res; 2004 Oct; 64(20):7562-9. PubMed ID: 15492283
[TBL] [Abstract][Full Text] [Related]
17. Cerivastatin demonstrates enhanced antitumor activity against human breast cancer cell lines when used in combination with doxorubicin or cisplatin.
Kozar K; Kaminski R; Legat M; Kopec M; Nowis D; Skierski JS; Koronkiewicz M; Jakóbisiak M; Golab J
Int J Oncol; 2004 May; 24(5):1149-57. PubMed ID: 15067336
[TBL] [Abstract][Full Text] [Related]
18. PNAS-4, a novel pro-apoptotic gene, can potentiate antineoplastic effects of cisplatin.
Yuan Z; Yan F; Wang YS; Liu HY; Gou LT; Zhao XY; Lai ST; Deng HX; Li J; Ding ZY; Xiong SQ; Kan B; Mao YQ; Chen LJ; Wei YQ; Zhao X
Cancer Chemother Pharmacol; 2009 Dec; 65(1):13-25. PubMed ID: 19387645
[TBL] [Abstract][Full Text] [Related]
19. Effects of lovastatin alone or combined with irradiation on tumor cells in vitro and in vivo.
Gabryś D; Dörfler A; Yaromina A; Hessel F; Krause M; Oertel R; Baumann M
Strahlenther Onkol; 2008 Jan; 184(1):48-53. PubMed ID: 18188523
[TBL] [Abstract][Full Text] [Related]
20. Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models.
Hoch U; Lynch J; Sato Y; Kashimoto S; Kajikawa F; Furutani Y; Silverman JA
Cancer Chemother Pharmacol; 2009 Jun; 64(1):53-65. PubMed ID: 18931998
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
